
Life Sciences Partners et al. in €32m round for Oxthera
Life Sciences Partners, Ysios Capital, Sunstone Capital and Flerie Invest have led a €32m investment round for Swedish drug developer Oxthera.
In addition to the Dutch, Spanish, Danish and Swedish VCs, the funding round also saw participation from Oxthera's existing backers: French VCs Kurma Partners and Idinvest, Swedish government-backed VC Industrifonden, and Sweden-based investment company Brohuvudet.
Oxthera's capital injection brings the total raised by the biotech business to more than €78m.
The funding will be used to continue development of the company's programme for treatment of primary hyperoxaluria, a potentially fatal disease where sufferers excrete excessive amounts of oxalate in their urine.
Previous funding
Prior to its most recent round, Oxthera had raised in excess of €46m in five rounds over the span of a decade, according to unquote" data.
It first raised SEK 165m from HealthCap and Scandinavian Life Science Ventures in July 2005, followed by a further €16m in 2007, when Industrifonden joined the two existing backers.
Industrifonden led an undisclosed follow-on round in June 2010, with HealthCap joining the Swedish VC in 2012 for an additional €4.67m investment.
In April 2014, HealthCap, Idinvest, Industrifonden and Kurma Partners participated in a €7.5m round for Oxthera.
Company
Oxthera is a Stockholm-based developer of treatments for hyperoxaluria.
The company was founded in 2005 and is developing hyperoxaluria drugs based on live oxalate-consuming bacteria, to prevent kidney damage in sufferers of the disease.
People
Oxthera – Elisabeth Lindner (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater